Bioinformatics analysis and sequence alignments performed in our laboratory proposed that miR-3174 can target many influential tumor-promoting genes involved in the pathobiology of GBM, including CD44, PLAU, MDM2, CDK6 and RHOA. The gene discussed is MDM2; the disease is glioblastoma.